{
    "id": 23640,
    "cites": 65,
    "cited_by": 1,
    "reference": [
        "Aguirregabiria, V. and P. Mira [2007], \"Sequential Estimation of Dynamic Discrete Games\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Econometrica, 75(1):1-53.",
        "Aitken, M., E.R. Berndt, D.M. Cutler, M. Kleinrock and L. Maini [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Has The Era Of Slow Growth for Prescription Drug Spending Ended?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Affairs 35(9):1595-1603.",
        "Barrett, J. [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Drug Companies Seek Consolidation Amid Pricing Pressures\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Pharmacy Times, January 19. Available online at http://www.pharmacytimes.com/publications/issue/2017/january2017/generic-drug-compani... Bajari, P., C. L. Benkard, and J. Levin [2007], \"Estimating Dynamic Models of Imperfect Competition\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Econometrica, 75(5):1331-1370.",
        "Berndt, E.R. and M.L. Aitken [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, International Journal of the Economics of Business, 18(2):177-201, July.",
        "Berndt, E.R., R.M. Conti and S.J. Murphy [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Generic Drug User Fee Amendments: An Economic Perspective\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Cambridge, MA: National Bureau of Economic Research, Working Paper No. 23642, August.",
        "Berndt, E.R., T.G. McGuire, J.P. Newhouse [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Forum for Health Economics and Policy, November, 14(2), Article 10. Available online at http://www.bepress.com/fhep/14/2/10.",
        "Berndt, E.R. and J.P. Newhouse [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing and Reimbursement in U.S. Pharmaceutical Markets\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 8 in Patricia M. Danzon and Sean N. Nicholson, eds., The Oxford Handbook on the Economics of the Biopharmaceutical Industry, New York: Oxford University Press, 201-265.",
        "Berry, S. and P. Reiss [2007], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Empirical Models of Entry and Market Structure\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 29 in Mark Armstrong and Robert Porter, eds., Handbook of Industrial Organization, Vol. 3, Amsterdam: North-Holland Elsevier, 1845-1886.",
        "Bresnahan, T.F. and P. Reiss [1988], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Entry Conditions Vary Across Markets?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Brookings Papers on Economic Activity: Microeconomics, 833-871.",
        "Bresnahan, T.F. and P. Reiss [1991], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Entry and Competition in Concentrated Markets\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Political Economy 99:977-1009.",
        "Carlton, D.W. and J.M. Perloff [2005], Modern Industrial Organization, Fourth Edition, Boston: Pearson Addison Wesley.",
        "Conti, R.M. and E.R. Berndt [2014], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Specialty Drug Prices and Utilization After Loss of U.S. Patent Exclusivity, 2001-2007\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Cambridge, MA: National Bureau of Economic Research, Working Paper No. 20016, March. Available online at http://www.nber.org/papers/w20016..",
        "Dave, C.V., A. S. Kesselheim, E. R. Fox, P. Qiu, A. Hartzema [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093High Generic Drug Prices and Market Competition: A Retrospective Cohort Study\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Annals of Internal Medicine, July. doi:10.7326/M16-1432.",
        "Deutsch, L.L. [1975], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Structure, Performance, and the Net Rate of Entry into Manufacturing Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Southern Economics Journal, 41:450-456.",
        "Dranove, D. [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Care Markets, Regulators and Certifiers\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 10 in Mark V. Pauly, Thomas G. McGuire, and Pedro P. Barros, eds., Handbook of Health Economics, Vol. 2, Amsterdam: North Holland Elsevier, 639-690.",
        "Duggan, M., P. Healy, and F.M. Scott Morton [2008], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Providing Prescription Drug Coverage to the Elderly: America's Experiment with Medicare Part D\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Economic Perspectives, Fall, 22(4):69-92.",
        "Duggan, M. and F.M. Scott Morton [2010], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Medicare Part D on Pharmaceutical Prices and Utilization\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, American Economic Review, March, 100(1):590-607.",
        "Dunne, T., M.J. Roberts, and L. Samuelson [1988], \"Patterns of Firm Entry and Exit in U.S. Manufacturing Industries\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, The Rand Journal of Economics, 19(4):495-515.",
        "Dusetzina, S.S., R.M. Conti, N. Yu, P.B. Bach [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Are Rebates in Part D Increasing Costs for Patients and Medicare?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of the American Medical Association - Internal Medicine, May 30.",
        "Economics Online [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Contestable Markets\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Available online at http://www.economicsonline.co.uk/Business_economics/Contestable_markets.html.",
        "Federal Trade Commission [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093HSR threshold adjustments and reportability for 2017\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Premerger Notification Office Staff, Bureau of Competition, February 7.",
        "Federal Trade Commission [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Authorized Generic Drugs: Short-Term Effects and LongTerm Impact\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, August. Available online at www.ftc.gov/opa/2011/08/genericdrugs.html.",
        "Fein, A.J. [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Retail Generic Drug Costs Go Up, Up, and Away\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, November 19. Available online at http://www.drugchannels.net/2013/11/retail-generic-drrugcosts -go-up-up-and.html.",
        "Fein, A.J. [2014a], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Retail Generic Drug Inflation Reaches New Heights\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, August 12. Available online at http://www.drugchannels.net/2014/08/retail-generic-druginflation -reaches.html.",
        "Fein, A.J. [2014b], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Winners and Losers from Generic Drug Inflation\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, August 13. Available online at http://www.drugchannels.net/2014/08/winners-and-losers-from-genericdrug. html.",
        "Fein, A.J. [2014c], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093In the Third Quarter, Retail Generic Drug Inflation Kept on Truckin\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, November 18. Available online at http://www.drugchannels.net/2014/11/in-thirdquarter -retail-generic-drug.html.",
        "Fein, A.J. [2015a], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Retail Generic Drug Inflation Eases, but the FDA Keeps Prices High\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, April 15. Available online at http://www.drugchnnels.net/2015/04/retail-genericdrug -inflation-eases-but.html.",
        "Fein, A.J. [2015b], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Retail Generic Drug Inflation Slowdown: It\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Real\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, August 25. Available online at http://www.drugchannels.net/2015/08/the-retail-generic-druginflation. html.",
        "Fein, A.J. [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The FDA Is Finally Ending Generic Inflation \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c and Hurting Wholesaler Profits\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, February 10. Available online at http://www.drugchannels.net/2016/02/the-fda-is-finally-ending-generic.html.",
        "Fein, A. J. [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Channels News Roundup, May 2017: Express Scripts, WBAD, DIR Fees, JAMA, and #Asembia17 Photos\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Channels, May 31. Available online at http://www.drugchannels.net;2017/05/drug-channels-news-roundup-may-2017.html.",
        "Frank, R.G. and D.S. Salkever [1997], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Entry and the Pricing of Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Economics & Management Strategy 6(1):75-90.",
        "Goedken, A.M., J.M. Urmie, K.B. Farris, W.R. Doucette [2010], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Impact of Cost Sharing on Prescription Drugs Used by Medicare Beneficiaries\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Research in Social and Administrative Pharmacy, June, 6(2):100-9.",
        "Gorecki, P.K. [1975], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Determinants of Entry by New and Diversifying Enterprises in the UK Manufacturing Sector, 1958-1963: Some Tentative Results.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Applied Economics, 7:139-147.",
        "Gorecki, P.K. [1976], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Determinants of Entry by Domestic and Foreign Enterprises in Canadian Manufacturing Industries: Some Comments and Empirical Results\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Review of Economics and Statistics 58:485-488.",
        "Grabowski, H., J.M. Vernon [1996], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Longer Patents for Increased Generic Competition in the US\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, PharmacoEconomics 10 Suppl. 2:101-123.",
        "Harding, D. [2010], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Gaining Market Share in the Generic Drug Industry Through Acquisitions and Partnerships\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, White Paper, Thomson Reuters, December. Available online at thomsonreuters.com.",
        "Hemphill, C.S. and B.N. Sampat [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Health Economics, 31, pp. 327-339.",
        "Herrick, D.M. [2015], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093What Is Increasing the Cost of Generic Drugs? (Part I: The Supply Chain\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Dallas, TX: National Center for Policy Analysis, Policy Report No. 371, September. Available online at www.ncpa.org.",
        "Herrick, D.M. [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Regulatory and Legal Reasons for Generic Drug Price Hikes\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Statement for the Record, Developments in the Prescription Drug Market, Hearings before the United States House of Representatives, Committee on Oversight and Government Reform, February 4. Available online at www.ncpa.org.",
        "IMS Institute for Healthcare Informatics [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicine use and Spending in the U.S.: A Review of 2015 and Outlook to 2020,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d April.",
        "Karst, K.R. [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093ANDA Arbitrage & the New ANDA Holder Program Fee Under GDUFA II\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Hyman, Phelps & McNamara, P. C., FDA Law Blog, June 28.",
        "McGuckin, R. [1972], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Entry, Concentration Change, and Stability of Market shares.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Southern Economics Journal 38:363-370.",
        "Orr, D. [1974], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Determinants of Entry: A Study of the Canadian Manufacturing Industries\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Review of Economics and Statistics 56(1):58-66.",
        "Pakes, A., M. Ostrovsky and S. Berry [2007], \"Simple Estimators for Parameters of Discrete Dynamic Games (with Entry/Exit Examples)\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, The Rand Journal of Economics, 38(2):373-399.",
        "Pesendorfer, M. and P. Schmidt-Dengler [2003], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Identification and Estimation of Dynamic Games\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Cambridge, MA: National Bureau of Economic Research, Working Paper 9726, May. Available online at http://www.nber.org/papers/29726.",
        "QuintilesIMS Institute, Medicines Use and Spending in the U.S.: A Review of 2016 and Outlook to 2021, May 2017, 46 pp. Available online at www.quintilesimsinstitute.org.",
        "Rockoff, J.D. [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Mylan faces scrutiny over EpiPen price increases\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, The Wall Street Journal, August 24. Available online at https://www.wsj.com/articles/mylan-faces-scrutiny-overepipen -price-increases-1472074823).",
        "Scherer, F.M. and D. Ross [1990], Industrial Market Structure and Economic Performance, Third Edition, Boston: Houghton Mifflin Company.",
        "Schmalensee, R. [1989], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Inter-Industry studies of Structure and Performance\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 16 in Richard Schmalensee and Robert D. Willig, eds., Handbook of Industrial Organization, Amsterdam: North Holland, 1989, pp. 951-1009.",
        "Scott Morton, F.M. and M. Kyle [2012], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Markets for Pharmaceutical Products\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 12 in Mark V. Pauly, Thomas G. McGuire, and Pedro P. Barros, eds., Handbook of Health Economics, Vol. 2, Amsterdam: North Holland Elsevier, 763-823.",
        "Scott Morton, F.M. [1999], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Entry Decisions in the Generic Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, RAND Journal of Economics 30(3):421-440.",
        "Silverman, E. [2014a], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Lawmakers probe \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093staggering\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d price hikes for generic drugs\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, WSJ Pharmalot, October 2. Available online at http://blogs.wsj.com/pharmalot/2014/10/02/lawmakers-probe-staggering-price-hikes-for-genericdrugs /).",
        "Silverman, E. [2014b], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Prices, Generics and M&A: What to Watch in 2015\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, WSJ Pharmalot, December 29.",
        "Sood, N., T. Shih, K. Van Nuys and D. Goldman [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Flow of Money Through the Pharmaceutical Distribution System\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, paper presented at the Brookings Institution, Washington DC, April 10, 2017.",
        "Stomberg, C. [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Shortages, Pricing, and Regulatory Activity\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Cambridge, MA: National Bureau of Economic Research, Working Paper No. 22912, December. Available online at http://www.nber.org/papers/w22912.",
        "Sutton, J. [1991], Sunk Costs and Market Structure, Cambridge, MA: MIT Press.",
        "Sutton, J. [2007], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Structure: Theory and Evidence\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 35 in Mark Armstrong and Robert Porter, eds., Handbook of Industrial Organization, Volume 3, Amsterdam: North Holland Elsevier, 2301-2368.",
        "Tirole, J. [1988], The Theory of Industrial Organization, Cambridge, MA: The MIT Press.",
        "U.S. Department of Health and Human Services, Assistant Secretary of Planning and Evaluation (ASPE) [2011], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Economic Analysis of the Causes of Drug Shortages\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Issue Brief, October.",
        "U.S. Department of Health and Human Services, Assistant Secretary of Planning and Evaluation (ASPE) [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Understanding Recent Trends in Generic Drug Prices\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Issue Brief, January 27. Available online at https://aspe.hhs.gov/pdf-report/understanding-recent-trends-genericdrug -prices.",
        "U.S. Department of Health and Human Services, Office of Inspector General [2006], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Food and Drug Administration\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s National Drug Code Directory\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, August, OEI-06-05-00060.",
        "U.S. Senate Special Committee on Aging [2016], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Sudden Price Spikes in Off-Patent Prescription Drugs: The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Health Care System\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Special Report, December. U.S. Government Printing Office. Available online at www.aging.senate.gov.",
        "Whinston, M.D. [2007], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Antitrust Policy Toward Horizontal Mergers\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 36 in in Mark Armstrong and Robert Porter, eds., Handbook of Industrial Organization, Volume 3, Amsterdam: North Holland Elsevier, 2369-2440.",
        "Woodcock, J. and M. Wosinska [2013], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Economic and Technological Drivers of Sterile Injectable Drug Shortages\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Clinical Pharmacology & Therapeutics 93(2):170-176. Available online at http://www.nature.com/clpt/journal/v93/n2/full/clpt20122220a.html.",
        "Yurukoglu, A., E. Liebman, and D.B. Ridley [2017], \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Role of Government Reimbursement in Drug Shortages\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, American Economic Journal Economic Policy, May 9(2):348-382."
    ]
}